These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38412735)

  • 41. Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
    Brenu EW; Ashton KJ; van Driel M; Staines DR; Peterson D; Atkinson GM; Marshall-Gradisnik SM
    J Affect Disord; 2012 Dec; 141(2-3):261-9. PubMed ID: 22572093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
    Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
    Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exosome-associated mitochondrial DNA from patients with myalgic encephalomyelitis/chronic fatigue syndrome stimulates human microglia to release IL-1β.
    Tsilioni I; Natelson B; Theoharides TC
    Eur J Neurosci; 2022 Nov; 56(10):5784-5794. PubMed ID: 36153118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME).
    Petty RD; McCarthy NE; Le Dieu R; Kerr JR
    PLoS One; 2016; 11(3):e0150904. PubMed ID: 26967895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies.
    Nilsson I; Palmer J; Apostolou E; Gottfries CG; Rizwan M; Dahle C; Rosén A
    Front Med (Lausanne); 2020; 7():108. PubMed ID: 32296708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surveying the Metabolic and Dysfunctional Profiles of T Cells and NK Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Maya J
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Lesslar OL; Deed G; Marshall-Gradisnik S
    Mol Med; 2022 Aug; 28(1):98. PubMed ID: 35986236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Campen CLMCV; Rowe PC; Visser FC
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056336
    [No Abstract]   [Full Text] [Related]  

  • 49. Altered endothelial dysfunction-related miRs in plasma from ME/CFS patients.
    Blauensteiner J; Bertinat R; León LE; Riederer M; Sepúlveda N; Westermeier F
    Sci Rep; 2021 May; 11(1):10604. PubMed ID: 34011981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME) / chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS.
    Twisk FN; Maes M
    Neuro Endocrinol Lett; 2009; 30(3):284-99. PubMed ID: 19855350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Who Have Already Visited Some Medical Institutions: The Points of Diagnosis and Treatment].
    Shimomura T
    Brain Nerve; 2022 May; 74(5):660-667. PubMed ID: 35589661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review.
    Maksoud R; Magawa C; Eaton-Fitch N; Thapaliya K; Marshall-Gradisnik S
    BMC Med; 2023 May; 21(1):189. PubMed ID: 37226227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Williams PhD MV; Cox B; Lafuse PhD WP; Ariza ME
    Clin Ther; 2019 May; 41(5):848-863. PubMed ID: 31040055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Submaximal exercise testing with near-infrared spectroscopy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients compared to healthy controls: a case-control study.
    Miller RR; Reid WD; Mattman A; Yamabayashi C; Steiner T; Parker S; Gardy J; Tang P; Patrick DM
    J Transl Med; 2015 May; 13():159. PubMed ID: 25990639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a mini-review.
    Tomas C; Newton J
    Biochem Soc Trans; 2018 Jun; 46(3):547-553. PubMed ID: 29666214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long Covid at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
    Hunt J; Blease C; Geraghty KJ
    J Health Psychol; 2022 Dec; 27(14):3106-3120. PubMed ID: 35341334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery.
    Gómez-Mora E; Carrillo J; Urrea V; Rigau J; Alegre J; Cabrera C; Oltra E; Castro-Marrero J; Blanco J
    Front Immunol; 2020; 11():582330. PubMed ID: 33329554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome.
    Giloteaux L; Goodrich JK; Walters WA; Levine SM; Ley RE; Hanson MR
    Microbiome; 2016 Jun; 4(1):30. PubMed ID: 27338587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Important factors to consider when treating children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): perspectives of health professionals from specialist services.
    Parslow RM; Shaw A; Haywood KL; Crawley E
    BMC Pediatr; 2017 Feb; 17(1):43. PubMed ID: 28143516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns.
    Trivedi MS; Oltra E; Sarria L; Rose N; Beljanski V; Fletcher MA; Klimas NG; Nathanson L
    PLoS One; 2018; 13(7):e0201066. PubMed ID: 30036399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.